Can a PD-1/VEGF bispecific raise the bar in advanced biliary tract cancer?

Phase III HARMONi-GI1: ivonescimab + chemo vs durvalumab + chemo in first-line BTC.
Median OS: 14.9 vs 12.1m (HR 0.75). Median PFS: 8.4 vs 5.8m (HR 0.61)

— @AmandaSunMD | #ESMO26 Takeover, Oct 25